This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pan, E. Articles by Feuerstein, B. G. Search for Related Content PubMed PubMed Citation Articles by Pan, E. Articles by Feuerstein, B. G.

Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients

Authors' Affiliations: ¹ University of California San Francisco, San Francisco, California; ² Children's Oncology Group, Arcadia, California; ³ Johns Hopkins University School of Medicine, Baltimore, Maryland; and ⁴ Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Requests for reprints: Shaun Mason, Children's Oncology Group, Publications Office, 440 East Huntington Drive, Suite 300, Arcadia, CA 91066. Phone: 626-447-0064; Fax: 626-445-4334; E-mail: smason{at}childrensoncologygroup.org.

Background: Medulloblastomas are the most common primary malignant childhood intracranial neoplasms. Patients are currently sorted into three risk groups based on clinical criteria: standard, poor, and infant (<18 months old). We hypothesized that genetic copy number aberrations (CNA) predict prognosis and would provide improved criteria for predicting outcome.

Methods: DNA from 35 medulloblastoma patients from four Children's Cancer Group trials was analyzed by comparative genomic hybridization to determine CNAs. The genetic alterations were evaluated using statistical and cluster analyses.

Results: The most frequent CNAs were gains on 17q, 7, 1q, and 7q and losses on 17p, 10q, X, 16q, and 11q. Amplification at 5p15.1-p15.3 was also detected. Isochromosome 17q (i(17)(q10)) was associated with poor overall survival (P = 0.03) and event-free survival (P = 0.04) independent of poor risk group classification. Age <3 tended to be associated with <3 CNAs (P = 0.06). Unsupervised cluster analysis sorted the study patients into four subgroups based on CNAs. Supervised analysis using the program Significance Analysis of Microarrays (SAM) quantitatively validated those CNAs identified by unsupervised clustering that significantly distinguished among the four subgroups.

Conclusions: Medulloblastomas are genetically heterogeneous and can be categorized into separate genetic subgroups by their CNAs using unsupervised cluster analysis and SAM. i(17)(q10) was a significant independent negative prognostic factor. Infant medulloblastomas may be a distinct genetic subset from those of older patients.

This article has been cited by other articles:

				S. Pfister, M. Remke, A. Benner, F. Mendrzyk, G. Toedt, J. Felsberg, A. Wittmann, F. Devens, N. U. Gerber, S. Joos, et al. Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the MYC and MYCN Loci J. Clin. Oncol., April 1, 2009; 27(10): 1627 - 1636. [Abstract] [Full Text] [PDF]

				L. Lafay-Cousin and D. Strother Current Treatment Approaches for Infants with Malignant Central Nervous System Tumors Oncologist, April 1, 2009; 14(4): 433 - 444. [Abstract] [Full Text] [PDF]

				T. J. MacDonald Aggressive Infantile Embryonal Tumors J Child Neurol, October 1, 2008; 23(10): 1195 - 1204. [Abstract] [PDF]

				J. M. de Bont, R. J. Packer, E. M. Michiels, M. L. d. Boer, and R. Pieters Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective Neuro-oncol, January 1, 2008; 10(6): 1040 - 1060. [Abstract] [Full Text] [PDF]

				K. C. Lo, C. Ma, B. N. Bundy, S. L. Pomeroy, C. G. Eberhart, and J. K. Cowell Gain of 1q Is a Potential Univariate Negative Prognostic Marker for Survival in Medulloblastoma Clin. Cancer Res., December 1, 2007; 13(23): 7022 - 7028. [Abstract] [Full Text] [PDF]

				F. Mendrzyk, B. Radlwimmer, S. Joos, F. Kokocinski, A. Benner, D. E. Stange, K. Neben, H. Fiegler, N. P. Carter, G. Reifenberger, et al. Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma J. Clin. Oncol., December 1, 2005; 23(34): 8853 - 8862. [Abstract] [Full Text] [PDF]